Daewoong Pharmaceutical and Chong Kun Dang will also enter the late-stage drug market for Vemlidy, a chronic hepatitis B treatment previously occupied by Dong-A ST. Daewoong and Chong Kun Dang's products received a month's delay in obtaining approvals, and their benefits were also applied a month later. According to the industry on the 20th, from March 1, Daewoong Pharmaceutical's Vemlidy and Chong Kun Dang's Tenofobell-A will be covered.

The two products are salt-modifying drugs of Gilead Sciences' 'Vemlidy'. Daewoong Vemlidy has Tenofovir Alafenamide HemiFumarate as the main ingredient, and Chong Kun Dang Tenofobell-A has Tenofovir Alafenamide Succinate as the main ingredient. These products succeed i